Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27741712 | 0.98 | AR (0.44) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL273364 | 0.84 | VNN1 (0.54) | ARMAOBPARP1ERN1KIF11 | |
| SCHEMBL30271464 | 0.84 | CES2 (0.47) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL2425056 | 0.84 | CES2 (0.47) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL11337669 | 0.84 | AR (0.43) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL1198272 | 0.84 | MAPT (0.54) | MAOBPARP1ERN1PDK2NOTUM | |
| SCHEMBL2873637 | 0.84 | LCK (0.48) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL30641942 | 0.84 | VNN1 (0.54) | ARMAOBPARP1ERN1KIF11 | |
| SCHEMBL1031838 | 0.84 | KIF11 (0.56) | ARMAOBPARP1ERN1PDK2 | |
| SCHEMBL6815102 | 0.84 | AR (0.42) | ARMAOBPARP1ERN1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | claimed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | claimed |
| EP-2491022-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | claimed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2491022-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-1945217-B1 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| CN-1391564-A | Chemical compounds | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
| WO-1993007907-A1 | TRIFLUOROMETHYL ANALOGS FOR F-19 NMR IMAGING | MALLINCKRODT MEDICAL, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | AR 406/4885MAOB 1646/4885PARP1 1753/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | AR 2006/4885MAOB 1468/4885PARP1 951/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | AR 1725/4885MAOB 1606/4885PARP1 920/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | AR 406/4885MAOB 1646/4885PARP1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.